Cerenis Therapeutics, the biopharmaceutical company, today announced that its Phase IIb CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis REgression) study did not reach its primary endpoint in post-Acute Coronary Syndrome ...
Tags: Cerenis Therapeutics, Phase IIb CHI-SQUARE, post-Acute Coronary Syndrome